CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9

Yan, Fancheng; Wang, William Yang; Zhang, Jiaqiang

doi:10.1007/s10565-019-09489-1

Cited by 73 publications

(51 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S4 C-H). These data are in agreement with other studies using similar approaches [51,69,70]. Taken together, this suggests that the Drosophila Cas13 variants tested here are highly specific and display no tolerance to a single mismatch in the core region of the spacer, and none of the enzymes were functional with two mismatches in the crRNA.…”

Section: Testing the Fidelity Of Drosophila Cas13 Variantssupporting

confidence: 93%

A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila

et al. 2020

View full text Add to dashboard Cite

Advances in CRISPR technology have immensely improved our ability to manipulate nucleic acids, and the recent discovery of the RNA-targeting endonuclease Cas13 adds even further functionality. Here, we show that Cas13 works efficiently in Drosophila, both ex vivo and in vivo. We test 44 different Cas13 variants to identify enzymes with the best overall performance and show that Cas13 could target endogenous Drosophila transcripts in vivo with high efficiency and specificity. We also develop Cas13 applications to edit mRNAs and target mitochondrial transcripts. Our vector collection represents a versatile tool collection to manipulate gene expression at the post-transcriptional level.

show abstract

Section: Testing the Fidelity Of Drosophila Cas13 Variantssupporting

confidence: 93%

A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These reports indicate the potential of the Cas13 enzyme as an effective antiviral to manage SARS-CoV-2 infection. (Yan F. et al, 2019 Applications of CRISPR-Cas as a Therapeutic Modality With Regard to COVID-19 and Future Prospects…”

Section: Crispr-cas Applicationsmentioning

confidence: 99%

CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics

Kumar

Malik

Ganesh

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

COVID-19, the human coronavirus disease caused by SARS-CoV-2, was reported for the first time in Wuhan, China in late 2019. COVID-19 has no preventive vaccine or proven standard pharmacological treatment, and consequently, the outbreak swiftly became a pandemic affecting more than 215 countries around the world. For the diagnosis of COVID-19, the only reliable diagnostics is a qPCR assay. Among other diagnostic tools, the CRISPR-Cas system is being investigated for rapid and specific diagnosis of COVID-19. The CRISPR-Cas-based methods diagnose the SARS-CoV-2 infections within an hour. Apart from its diagnostic ability, CRISPR-Cas system is also being assessed for antiviral therapy development; however, till date, no CRISPR-based therapy has been approved for human use. The Prophylactic Antiviral CRISPR in huMAN cells (PAC-MAN), which is Cas 13 based strategy, has been developed against coronavirus. Although this strategy has the potential to be developed as a therapeutic modality, it may face significant challenges for approval in human clinical trials. This review is focused on describing potential use and challenges of CRISPR-Cas based approaches for the development of rapid and accurate diagnostic technique and/or a possible therapeutic alternative for combating COVID-19. The assessment of potential risks associated with use of CRISPR will be important for future clinical advancements.

show abstract

“…Of these, type I and III systems use a large multi-Cas protein complex to promote the target sequence cleavage, whereas the type II system utilizes a single nuclease called Cas9 [15,16]. Cas12 and Cas13 are nuclease proteins belonging to type V and VI, respectively [17]. In this review, we focus on three important types of CRISPR/Cas systems.…”

Section: Types Of Crispr Systemsmentioning

confidence: 99%

“…One of the most important CRISPR-associated tools is CRISPR from Prevotella and Francisella 1 (CRISPR-Cpf1) which is analogous to the CRIS-PR-Cas9. Zhang and co-workers for the first time introduced the CRISPR-Cpf1 system in which the sgRNA-endonuclease protein differs from that of the CRISPR-Cas9 system [17] (Fig. 3).…”

Section: Crispr-cpf1(cas12)mentioning

confidence: 99%

An overview of applications of CRISPR-Cas technologies in biomedical engineering

Jamehdor¹,

Kaboli

Naserian

et al. 2020

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR) is one of the major genome editing systems and allows changing DNA levels of an organism. Among several CRISPR categories, the CRISPR-Cas9 system has shown a remarkable progression rate over its lifetime. Recently, other tools including CRISPR-Cas12 and CRISPR-Cas13 have been introduced. CRISPR-Cas9 system has played a key role in the industrial cell factory's production and improved our understanding of genome function. Additionally, this system has been used as one of the major genome editing systems for the diagnosis and treatment of several infectious and non-infectious diseases. In this review, we discuss CRISPR biology, its versatility, and its application in biomedical engineering.

show abstract

CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9

Cited by 73 publications

References 21 publications

A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila

A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila

CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics

An overview of applications of CRISPR-Cas technologies in biomedical engineering

Contact Info

Product

Resources

About